medigraphic.com
SPANISH

Anales de Radiología, México

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2006, Number 2

<< Back Next >>

Anales de Radiología México 2006; 5 (2)

Lymphomas, new classification and treatment. Incidence of lesions in the Hospital San José from 1990 to 2004. Clinical-radiological correlation.

Cano MI, Escobar PA, Isassi CA, Treviño M, Vázquez NJ
Full text How to cite this article

Language: Spanish
References: 5
Page: 117-136
PDF size: 411.09 Kb.


Key words:

Lymphomas, chemotherapy, genetic findings.

ABSTRACT

Introduction: Lymphomas are a variety of malignant lesions that differ according to its genetic findings, clinical presentation, therapeutic management and presentation. As years go by, new therapies with better results have been accomplished, such as rituximab, as well as new chemotherapies using bleomicine, etopsoside, doxorubicine, ciclofosfamide, vincristine, procarbazide and prednisone.
Objective: To acknowledge the incidence of lymphomas, their pathological lineage, their previous and actual classification, as well as the modification in their therapeutic strategies
Material and methods: 167 patients were selected, 101 males and 66 females with diagnosis of lymphoma studied and treated in the Hospital San José Tec de Monterrey from 1990 to 2005.
Results: The higher incidence was shown between the 6th and 7th life decade with 31 and 27 cases, respectively. The greater statistical volume matched with Non-Hodgking lymphomas with 92 patients. The main affections were ganglionar growth, mediastine, retroperitoneum and inguinal regions.
Conclusions: The evolution of lymphoma tumoral activity diagnosis, the advent of Computed Tomography and nuclear medicine, its combination with PET-CT method allow to identify small lesions with tumoral activity, by radioisotope-collecting such as F18 at the expense of dextrose aggregates that allow to identify tumoral activity, even in small lesions.


REFERENCES

  1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.

  2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting- Airlie House, Virginia. J Clin Oncol 1999; 17: 3835-49.

  3. Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of retreatment. J Clin Oncol 2000; 18: 3135-43.

  4. Ghielmini M, Schmitz S-FH, Cogliatti S, et al. Prolonged treatment with rituximab significantly improves event free survival and duration of response in patients with follicular lymphoma: a randomised SAKK trial. Blood 2002; 100: 161a.

  5. Chenson BD. Whats is new in lymphoma? CA Cancer J Clin 2004; 54: 260-72.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Anales de Radiología México. 2006;5